



Galapagos

Near-term Catalysts

4Q18	1Q19	2Q19	3Q19	4Q19
<p>2451+2222+2737 Phase Ib in δF508 CF interim (FALCON)</p> <p>✓ GLPG1690 Phase III IPF begins (ISABELA)</p> <p>✓ GLPG1205 Phase IIa IPF begins</p>	<p>✓ filgotinib Phase III FINCH-1 RA MTX-IRs data</p> <p>✓ filgotinib Phase III FINCH-3 RA MTX-naive data</p>	<p>✓ filgotinib ★ Update on US regulatory path</p>	<p>filgotinib Phase II Sjogren's syndrome data</p> <p>filgotinib Phase III PsA begins</p>	<p>filgotinib ★ Potential filings in RA</p> <p>filgotinib Phase II results in CLE</p> <p>filgotinib Phase III AS begins</p> <p>GLPG3312 (Toledo) Phase I data</p> <p>MOR106 Phase I subcut. dosing data</p>

2020		2021		2022
<p>filgotinib Phase II lupus MN & MANTA male safety data</p>	<p>filgotinib Potential approvals in RA</p>	<p>filgotinib Phase II results in non-infectious uveitis</p>		
<p>filgotinib Phase IIb/III SELECTION UC data</p>	<p>filgotinib Potential UC filings</p>	<p>filgotinib Phase III DIVERSITY CD results</p>	<p>filgotinib Potential UC approvals & CD filings</p>	<p>filgotinib Potential CD approvals</p>
<p>MOR106 Phase II IGUANA atopic dermatitis results</p>	<p>GLPG1972 Phase II OA results (ROCCELLA)</p>			
<p>GLPG1690 Phase IIa SSc results (NOVESA)</p>	<p>GLPG1690 Phase III IPF interim (ISABELA)</p>		<p>GLPG1690 Phase III IPF results (ISABELA) Potential filings</p>	<p>GLPG1690 Potential approvals for IPF</p>
<p>GLPG1205 Phase IIa PINTA IPF results</p>				